A tumor growth rate/overall survival model for atezolizumab as an early predictor of OS in patients with first or second line metastatic urothelial carcinoma.

被引：6

作者：

Bruno, Rene

Claret, Laurent

Wu, Benjamin

Jin, Jin Y.

Winter, Helen

Cui, Na

Derleth, Christina Louise

Shen, Xiaodong

Girish, Sandhya

Rosenberg, Jonathan E.

Powles, Thomas

机构：

[1] Roche Genentech, Clin Pharmacol, Marseille, France

[2] Genentech Roche, Peypin, France

[3] Genentech Roche, Clin Pharmacol, South San Francisco, CA USA

[4] Genentech Inc, San Francisco, CA USA

[5] Clin Pharmacol, Roche Genentech, San Francisco, CA USA

[6] Genentech Inc, South San Francisco, CA USA

[7] Genentech Inc, South San Francisco, CA USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY USA

[9] Queen Mary Univ London, Barts Canc Inst, London, England

来源：

关键词：

D O I：

10.1200/JCO.2018.36.5_suppl.62

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2